{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","groups":[{"description":"Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.","id":"OG000","title":"Temozolomide"}],"paramType":"NUMBER","populationDescription":"Glioblastoma patients","reportingStatus":"POSTED","timeFrame":"at 6 months","title":"Progression-free Survival (PFS) Rate at 6 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}